查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451722

2024-2032 年按药物类型、治疗领域、最终用户和地区分類的免疫疗法药物市场报告

Immunotherapy Drugs Market Report by Drug Type, Therapy Area, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2023年全球免疫疗法药物市场规模达2,130亿美元。展望未来， IMARC Group预计到2032年市场规模将达到4,255亿美元，2024-2032年复合年增长率（CAGR）为7.75%。由于人口老化，不同癌症类型的盛行率不断上升，对个人化药物的需求不断增长，以及个人对早期检测和治疗的意识不断增强，是推动市场的一些主要因素。

免疫治疗药物是一种旨在利用或改变免疫系统来对抗或控制疾病的医学治疗方法。它们专注于特定的细胞和蛋白质，有助于最大限度地减少对健康组织的伤害。与其他治疗方法相比，它们可以降低产生抗药性的可能性，提供更好的结果，并且副作用更少。它们用于治疗各种类型的癌症，包括黑色素瘤、肺癌和乳腺癌。它们也用于控制特定的过敏反应和治疗类风湿性关节炎、狼疮和多发性硬化症等疾病。除此之外，由于它们能有效控制慢性发炎性疾病，全球对免疫疗法药物的需求正在增加。

製药业的崛起和全球药局的扩张提供了良好的市场前景。此外，生物技术公司、製药公司和研究机构之间的策略合作和併购（M＆A）正在支持免疫疗法产品的研究、开发和商业化活动。此外，人工智慧（AI）和巨量资料分析在研发（R＆D）活动中的整合正在提高效率和精确度。这种技术整合能够快速识别目标、优化临床试验以及预测患者反应。

免疫治疗药物市场趋势/驱动因素：

目标疾病盛行率不断上升

由于生活方式的改变和不健康的饮食模式，不同类型癌症的发生率不断上升，这促使对免疫疗法等创新和有效治疗方法的需求不断增长。此外，早期检测和对个人化治疗方案的需求正在鼓励患者和医疗保健提供者采用这些先进的治疗方案。除此之外，快速的城市化和有害车辆排放造成的污染水平上升正在导致各种慢性疾病，这为免疫疗法创造了新的机会。此外，人口老化日益严重，极易患肿瘤、癌症和其他健康状况，这推动了对有效治疗和技术（如免疫疗法药物）的需求。

采用个人化药物

个人化药物在各个医疗领域的使用越来越多，以促进更以患者为中心的方法，这对市场产生了积极影响。此外，先进诊断工具（例如下一代定序和生物标记分析）的开发使得能够精确识别患者以进行特定免疫疗法。这些诊断学的进步促进了早期干预并允许个性化治疗计划，这有助于提高免疫疗法的整体有效性。除此之外，个人化免疫疗法也减少了试误方法的可能性。此外，这种有针对性的方法可以最大限度地减少无效治疗的使用，避免不必要的副作用，促进更快的康復，并降低医疗成本，这有助于市场成长。

政府和监管支持

各国政府和监管机构持续关注免疫疗法药物和疗法的开发，市场前景良好。此外，他们也为开发新型免疫疗法和优化现有免疫疗法所需的深入研究提供财政支持。除此之外，政府、研究机构和私人公司之间的合作正在支持市场成长。这些合作促进了知识交流并加速了突破性跨境免疫疗法的发展。此外，多项支持性政府医疗保健政策的推出正在鼓励免疫疗法的采用和报销。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球免疫治疗药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 单株抗体
    • 市场走向
    • 市场预测
  • 疫苗
    • 市场走向
    • 市场预测
  • 干扰素α和β
    • 市场走向
    • 市场预测
  • 白血球介素
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依治疗领域

  • 癌症
    • 市场走向
    • 市场预测
  • 自体免疫疾病与发炎性疾病
    • 市场走向
    • 市场预测
  • 传染性疾病
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 诊所
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A6639

The global immunotherapy drugs market size reached US$ 213.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 425.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.75% during 2024-2032. The growing prevalence of different cancer types due to the aging population, rising demand for personalized medicines, and the increasing awareness among individuals about early detection and treatment are some of the major factors propelling the market.

Immunotherapy drugs are medical treatments designed to utilize or modify the immune system to fight or control diseases. They focus on specific cells and proteins and aid in minimizing harm to healthy tissues. They reduce the likelihood of developing resistance, offer better outcomes, and have fewer side effects as compared to other treatments. They are utilized in treating various types of cancers, including melanoma, lung, and breast cancer. They are also used in managing specific allergic reactions and treating diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Besides this, as they are effective in controlling chronic inflammatory diseases, the demand for immunotherapy drugs is increasing across the globe.

The rise in the pharmaceutical industry and the expansion of pharmacies worldwide is offering a favorable market outlook. Moreover, strategic collaborations and mergers and acquisitions (M&A) between biotech firms, pharmaceutical companies, and research institutions are supporting the research, development, and commercialization activities of immunotherapy products. Furthermore, the integration of artificial intelligence (AI) and big data analytics in research and development (R&D) activities is enhancing efficiency and precision. This technological integration is enabling the rapid identification of targets, optimization of clinical trials, and prediction of patient responses.

Immunotherapy Drugs Market Trends/Drivers:

The increasing prevalence of target diseases

The rising occurrence of different types of cancer due to lifestyle changes and unhealthy dietary patterns is catalyzing the demand for innovative and effective treatments like immunotherapy is growing. Additionally, the early detection and need for personalized therapy options are encouraging patients and healthcare providers to adopt these advanced treatment alternatives. Apart from this, rapid urbanization and rising pollution levels due to harmful vehicular emissions are resulting in various chronic diseases, which is creating new opportunities for immunotherapy treatments. Furthermore, the increasing aging population, which is highly susceptible to tumor, cancer, and other health conditions, is driving the need for effective treatments and technologies, like immunotherapy drugs.

Adoption of personalized medicines

The increasing utilization of personalized medicines in various medical fields to promote a more patient-centered approach is positively influencing the market. Additionally, the development of advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, is enabling the precise identification of patients for specific immunotherapies. These advancements in diagnostics facilitate early intervention and allow for personalized treatment plans, which aid in enhancing the overall effectiveness of immunotherapy. Apart from this, personalized immunotherapies reduce the likelihood of trial-and-error approaches. Furthermore, this targeted approach minimizes the use of ineffective treatments, avoids unnecessary side effects, facilitates quicker recoveries, and reduces healthcare costs, which is contributing to market growth.

Governmental and regulatory support

Governments and regulatory bodies of various countries are continuously focusing on the development of immunotherapy drugs and therapies, which is offering a favorable market outlook. Additionally, they are providing financial support for conducting the in-depth studies required to develop novel immunotherapies and optimize existing ones. Apart from this, partnerships between governments, research institutions, and private companies are supporting market growth. These collaborations facilitate knowledge exchange and accelerate the development of groundbreaking immunotherapy treatments across borders. Furthermore, the introduction of several supportive governmental healthcare policies is encouraging the adoption and reimbursement of immunotherapies.

Immunotherapy Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immunotherapy drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, therapy area and end user.

Breakup by Drug Type:

Monoclonal Antibodies

Vaccines

Interferons Alpha and Beta

Interleukins

Monoclonal antibodies represent the largest market segment

A detailed breakup and analysis of the market based on the drug type has also been provided in the report. This includes monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins. According to the report, monoclonal antibodies accounted for the largest market share. These antibodies offer a highly specific and targeted approach. They are designed to attach distinct proteins and receptors on the surface of diseased cells, enabling precise intervention. Additionally, regulatory bodies support monoclonal antibody therapies, providing streamlined approval processes and encouraging rapid development and commercialization. Apart from this, ongoing research and investment into the development of monoclonal antibodies contribute to their dominant position in the market. Furthermore, increasing funding and collaboration within the scientific community continue to yield innovative solutions. Moreover, technological advancements in manufacturing processes are making the production of monoclonal antibodies more scalable and cost-effective.

Breakup by Therapy Area:

Cancer

Autoimmune and Inflammatory Diseases

Infectious Diseases

Others

Cancer accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the therapy area. This includes cancer, autoimmune and inflammatory diseases, infectious diseases, and others. According to the report, cancer represented the largest segment. The rising prevalence of cancer due to the aging population, lifestyle changes, and environmental factors represent one of the key factors positively influencing the market. Additionally, the growing awareness among individuals about the benefits of early diagnosis and treatment of cancer is catalyzing the demand for immunotherapy drugs. Immunotherapy offers targeted treatments that can identify and attack specific cancer cells, minimizing damage to healthy tissue, enhancing effectiveness, and reducing side effects. Apart from this, continuous investments from governmental bodies, private sectors, and philanthropic organizations are supporting cancer research, including the development of immunotherapies, which is offering a favorable market outlook. Furthermore, rising partnerships between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development and accessibility of cancer immunotherapies.

Breakup by End User:

Hospitals

Clinics

Others

Hospitals hold the majority of the market share

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals hold the largest market share. Hospitals have a multidisciplinary team of specialists, including oncologists, immunologists, pharmacists, and nurses. These integrated teams enable a collaborative approach to patient care, ensuring the appropriate application and monitoring of immunotherapies. Additionally, they are equipped with state-of-the-art medical technologies and equipment. This access allows for the utilization of advanced immunotherapies. Apart from this, collaborations with pharmaceutical companies allow hospitals to gain early access to new immunotherapy drugs and technologies. These partnerships enhance the ability of hospitals to offer cutting-edge treatment options. Furthermore, they have established relationships with insurance providers and a better understanding of reimbursement policies. Moreover, many hospitals are involved in clinical trials and research collaborations, actively contributing to the advancement of immunotherapy.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest immunotherapy drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share as the region has a well-established healthcare infrastructure that allows for the efficient distribution and utilization of immunotherapy drugs. Sophisticated medical facilities and well-trained healthcare professionals facilitate the widespread adoption of these treatments. Additionally, the region witnesses substantial investments from public and private sectors in healthcare and biotechnology, which facilitates research, drug development, and commercialization of immunotherapy products. Apart from this, the regulatory bodies in North America, such as the Food and Drug Administration (FDA), offer a conducive environment for drug approval. Furthermore, strategic collaborations between academia, biotech firms, and pharmaceutical companies ensure a dynamic environment for continuous innovation and growth in the field of immunotherapy.

Competitive Landscape:

Companies are actively engaged in various activities to stay competitive and innovate. They are conducting extensive research and development (R&D) activities, working on discovering new targets and optimizing existing therapies. Additionally, these companies are forming strategic partnerships with academic institutions, leveraging their expertise to fuel innovation. Apart from this, they are investing in cutting-edge manufacturing technologies to produce immunotherapy drugs efficiently and at scale. Furthermore, regulatory teams within these companies are collaborating with governmental bodies to ensure compliance with emerging rules and gain expedited approvals for novel treatment. Moreover, many companies are actively participating in international conferences and symposia, sharing knowledge, and learning from global peers.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca plc

Bayer AG

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

F. Hoffmann-La Roche AG

GSK plc

Merck & Co. Inc.

Pfizer Inc.

Sanofi S.A.

Recent Developments:

In January 2022, Pfizer Inc. and BioNTech SE entered a strategic collaboration to develop an mRNA-based vaccine to prevent shingles.

In March 2023. Sanofi S.A. announced that it has received marketing authorization for Dupixent (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in children.

In January 2021, Enara Bio and Boehringer Ingelheim International GmbH announced a strategic collaboration and licensing agreement for the research and development (R&D) of novel targeted cancer immunotherapy.

Key Questions Answered in This Report

  • 1. How big is the global immunotherapy drugs market?
  • 2. What is the expected growth rate of the global immunotherapy drugs market during 2024-2032?
  • 3. What are the key factors driving the global immunotherapy drugs market?
  • 4. What has been the impact of COVID-19 on the global immunotherapy drugs market?
  • 5. What is the breakup of the global immunotherapy drugs market based on the drug type?
  • 6. What is the breakup of the global immunotherapy drugs market based on the therapy area?
  • 7. What is the breakup of the global immunotherapy drugs market based on the end user?
  • 8. What are the key regions in the global immunotherapy drugs market?
  • 9. Who are the key players/companies in the global immunotherapy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunotherapy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Interferons Alpha and Beta
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Interleukins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune and Inflammatory Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim International GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Immunotherapy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Immunotherapy Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Immunotherapy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Immunotherapy Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Immunotherapy Drugs Market: Breakup by Therapy Area (in %), 2023
  • Figure 6: Global: Immunotherapy Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Immunotherapy Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Immunotherapy Drugs (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Immunotherapy Drugs (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Immunotherapy Drugs (Interleukins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Immunotherapy Drugs (Interleukins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Immunotherapy Drugs (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Immunotherapy Drugs (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Immunotherapy Drugs (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Immunotherapy Drugs (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Immunotherapy Drugs (Other Therapy Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Immunotherapy Drugs (Other Therapy Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Immunotherapy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Immunotherapy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Immunotherapy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Immunotherapy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Immunotherapy Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Immunotherapy Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Immunotherapy Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Immunotherapy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Immunotherapy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Immunotherapy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunotherapy Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Immunotherapy Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Immunotherapy Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
  • Table 4: Global: Immunotherapy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Immunotherapy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Immunotherapy Drugs Market: Competitive Structure
  • Table 7: Global: Immunotherapy Drugs Market: Key Players